Form 4: Pfizer Director Cyrus Taraporevala Acquires Over 1,500 Phantom Stock Units as Deferred Compensation

Pfizer Inc. Director Cyrus Taraporevala acquired 1,547.03 phantom stock units as deferred compensation, increasing his total beneficial ownership to 21,601.073 units.

Summary

• Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), acquired 1,547.03 phantom stock units.
• The transaction occurred on June 30, 2025.
• Each phantom stock unit represents one phantom share of common stock.
• The units were acquired at a price of $24.24 per unit.
• These units are part of deferred director's compensation, including dividend equivalents.
• The units will be settled in cash or common stock at the director's election following retirement from the Board of Directors.
• Following this transaction, Taraporevala beneficially owns a total of 21,601.073 phantom stock units.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by a director is generally a positive signal, indicating alignment of interests and a routine compensation event. It does not reflect operational performance but rather a standard governance practice.

Positives

• The acquisition of phantom stock units by a director aligns their interests with shareholders, as these units are tied to the company's stock performance.
• The transaction represents deferred compensation, indicating a structured approach to executive remuneration.

Risks

• The value of the phantom stock units is tied to Pfizer's common stock price, meaning their value could decrease if the stock price declines.
• Settlement in cash or common stock upon retirement introduces a future variable based on the stock price at that time.

Future Outlook

The phantom stock units represent deferred compensation that will be settled in cash or common stock at the director's election following retirement from the Board of Directors.

Industry Context

This transaction is a routine insider filing for deferred compensation, common in large publicly traded companies like Pfizer. It reflects standard corporate governance practices for compensating board members, aligning their long-term interests with shareholder value.

Comparison to Industry Standards

• This type of deferred compensation, often involving phantom stock or restricted stock units, is a common practice across the pharmaceutical and broader corporate sectors for non-employee directors.
• It aligns director incentives with long-term company performance, similar to compensation structures seen at companies like Johnson & Johnson, Merck, or Bristol Myers Squibb, which also utilize equity-based compensation for their board members.
• The specific value and number of units are relative to Pfizer's scale and compensation policies.

Corporate Governance

Stakeholder Impact

• Shareholders: Director's interests are further aligned with shareholder value through equity-linked compensation.

Next Steps

• The phantom stock units will be settled in cash or common stock upon Cyrus Taraporevala's retirement from the Board of Directors.

Key Dates

Recommendation

Keywords

Pfizer, PFE, Form 4, SEC filing, Cyrus Taraporevala, Director compensation, Phantom stock units, Deferred compensation, Insider transaction, Stock acquisition